Market Overview

resTORbio CEO Chen Schor, In Benzinga Interview, Gives Timeline For Upcoming Clinical Updates On RTB101: Sees End Of Phase 2 Meeting With FDA Around Q4, To Initiate 2 Pivotal Clinical Studies In 2019, Sees Filing Of NDA In 2020

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: Biotech News FDA Market-Moving Exclusives Exclusives Interview General

 

Related Articles (TORC)

Upcoming Earnings: Oil Supermajors Chevron And ExxonMobil To Report Friday Morning

Facebook 'Hit Reset' On Expectations: Wall Street Responds To The Lackluster Quarter